Your browser is no longer supported. Please, upgrade your browser.
ANIP [NASD]
ANI Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.88 Insider Own5.50% Shs Outstand12.00M Perf Week4.95%
Market Cap433.65M Forward P/E7.97 EPS next Y4.39 Insider Trans1.34% Shs Float9.54M Perf Month8.93%
Income-22.50M PEG- EPS next Q0.71 Inst Own80.80% Short Float5.53% Perf Quarter14.90%
Sales208.50M P/S2.08 EPS this Y-478.40% Inst Trans0.30% Short Ratio9.50 Perf Half Y24.51%
Book/sh16.31 P/B2.15 EPS next Y22.27% ROA-4.80% Target Price- Perf Year-5.30%
Cash/sh0.64 P/C54.89 EPS next 5Y2.20% ROE-11.50% 52W Range23.55 - 40.62 Perf YTD20.52%
Dividend- P/FCF47.14 EPS past 5Y-27.90% ROI-3.30% 52W High-13.84% Beta1.29
Dividend %- Quick Ratio1.40 Sales past 5Y22.30% Gross Margin58.20% 52W Low48.62% ATR1.48
Employees369 Current Ratio2.20 Sales Q/Q19.40% Oper. Margin-7.70% RSI (14)60.18 Volatility4.28% 4.25%
OptionableYes Debt/Eq0.95 EPS Q/Q24.40% Profit Margin-10.80% Rel Volume1.11 Prev Close35.06
ShortableYes LT Debt/Eq0.88 EarningsMay 07 BMO Payout- Avg Volume55.52K Price35.00
Recom2.00 SMA204.67% SMA507.85% SMA20015.36% Volume61,901 Change-0.17%
May-07-20Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-12-19Initiated Guggenheim Buy
May-10-19Downgrade Raymond James Strong Buy → Outperform $73 → $82
Oct-16-17Reiterated Canaccord Genuity Buy $60 → $66
Jul-31-17Initiated Canaccord Genuity Buy $60
Feb-22-17Downgrade ROTH Capital Buy → Neutral
Jun-23-16Initiated Raymond James Strong Buy $68
May-24-16Downgrade Standpoint Research Buy → Hold
Nov-13-15Initiated Standpoint Research Buy $54
Sep-28-15Upgrade ROTH Capital Neutral → Buy $67 → $60
Aug-05-15Reiterated Oppenheimer Outperform $74 → $65
Aug-04-15Reiterated ROTH Capital Neutral $70 → $67
Jul-31-15Reiterated Oppenheimer Outperform $72 → $74
Jul-15-15Reiterated ROTH Capital Neutral $60 → $70
Jun-23-15Reiterated Oppenheimer Outperform $61 → $67
May-18-15Reiterated ROTH Capital Neutral $78 → $60
May-06-15Reiterated Oppenheimer Outperform $69 → $61
Apr-10-15Downgrade ROTH Capital Buy → Neutral $78
Feb-26-15Reiterated ROTH Capital Buy $65 → $78
Feb-18-15Reiterated Oppenheimer Outperform $58 → $69
Apr-30-21 03:00PM  
Apr-27-21 01:41PM  
01:24PM  
Apr-26-21 04:30PM  
Apr-06-21 06:50AM  
Mar-22-21 06:27AM  
Mar-09-21 01:00PM  
08:05AM  
06:50AM  
06:45AM  
05:30AM  
Mar-08-21 10:18AM  
Mar-07-21 01:25AM  
Mar-02-21 12:30PM  
Feb-19-21 04:30PM  
Feb-17-21 06:50AM  
Feb-16-21 04:30PM  
Feb-01-21 06:50AM  
Jan-06-21 12:13AM  
Dec-17-20 06:50AM  
Dec-03-20 09:50PM  
Nov-17-20 10:32AM  
Nov-07-20 07:44AM  
Nov-05-20 04:01PM  
06:50AM  
Oct-29-20 06:50AM  
Oct-28-20 12:32PM  
Sep-10-20 07:00PM  
Aug-06-20 08:35AM  
06:50AM  
06:45AM  
Aug-03-20 06:50AM  
Jul-30-20 06:50AM  
Jul-29-20 12:33PM  
Jul-08-20 07:38AM  
Jul-06-20 08:30AM  
Jul-04-20 08:54PM  
Jun-30-20 08:30AM  
Jun-14-20 11:38PM  
Jun-01-20 08:30AM  
May-09-20 08:21AM  
May-08-20 06:30PM  
May-07-20 09:55AM  
08:30AM  
May-01-20 11:50AM  
Apr-30-20 08:30AM  
Apr-29-20 08:30AM  
Apr-24-20 06:45AM  
Apr-14-20 08:30AM  
Apr-13-20 08:30AM  
Apr-02-20 08:30AM  
Mar-26-20 08:30AM  
Mar-24-20 08:30AM  
Mar-11-20 03:37PM  
Mar-10-20 06:40AM  
Mar-05-20 07:17AM  
Mar-02-20 08:30AM  
Feb-29-20 07:35AM  
Feb-27-20 10:05AM  
08:30AM  
Feb-24-20 12:45PM  
Feb-21-20 05:25AM  
Feb-20-20 08:30AM  
Feb-19-20 12:31PM  
Feb-12-20 08:30AM  
Jan-24-20 08:30AM  
Jan-16-20 08:30AM  
05:39AM  
Jan-14-20 08:30AM  
Jan-09-20 08:30AM  
Dec-19-19 10:09AM  
Dec-18-19 08:30AM  
Dec-11-19 01:55PM  
05:06AM  
Dec-04-19 09:21AM  
07:45AM  
Nov-26-19 08:30AM  
Nov-22-19 05:19PM  
Nov-11-19 06:25AM  
Nov-06-19 09:55AM  
08:30AM  
08:21AM  
Oct-31-19 08:30AM  
Oct-30-19 08:30AM  
Oct-29-19 10:33AM  
08:30AM  
Oct-28-19 04:14PM  
Oct-12-19 08:26AM  
Oct-11-19 12:18PM  
Oct-10-19 10:37AM  
Oct-09-19 09:09AM  
Oct-03-19 08:30AM  
Oct-02-19 08:30AM  
Sep-29-19 11:39AM  
Sep-12-19 06:57AM  
Sep-11-19 08:30AM  
Sep-05-19 06:43PM  
Aug-13-19 08:08AM  
Aug-07-19 01:23PM  
09:45AM  
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walsh Patrick DDirectorMar 15Buy32.894,000131,55539,096Mar 17 07:55 PM
Walsh Patrick DDirectorNov 09Buy25.965,000129,80035,096Nov 12 05:11 PM
Walsh Patrick DCHAIRMAN, INTERIM PRES. & CEOAug 10Buy30.7810,000307,79030,096Aug 12 04:18 PM